Clinical trials: Glial Tumor
Brain and Central Nervous System Tumors
Gadolinium Texaphyrin Plus Radiation Therapy in Treating Patients With Supratentorial Glioblastoma Multiforme
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs such as gadolinium texaphyrin may make tumor cells more sensitive to radiation therapy.
- Trial name
- NCT00006452
- Testing
- motexafin gadolinium, radiation therapy
- Volunteers
- 6 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Brain and Central Nervous System Tumors
Carboplatin in Patients With Progressive Gliomas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carboplatin in patients with progressive glioma.
- Trial name
- NCT00002749
- Testing
- carboplatin
- Where
- 2 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Duke University
Bladder Cancer, Kidney Cancer
Ex VIvo DEtermiNed Cancer Therapy
EVIDENT's aim is to test if ex vivo drug screening can predict whether patients with solid cancers will respond, or not respond, to standard care treatments.
- Conditions
- Bladder Cancer, Kidney Cancer, Melanoma, Sarcoma
- Trial name
- EVIDENT (NCT05231655)
- Testing
- Functional drug screen
- Where
- United Kingdom
- Volunteers
- 600 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Propofol, Glioma
Effects of Propofol on Auditory Event-related Potentials and Brain Functional Connectivity in Patients With Supratentorial Glioma
The growth of gliomas often infiltrates important brain tissues and impairs subcortical fiber transmission, resulting in changes in global brain network connectivity.
- Conditions
- Propofol, Glioma, Auditory Event-related Potential (AERP), Electroencephalogram (EEG)
- Trial name
- NCT05352685
- Testing
- Propofol Injection
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Beijing Tiantan Hospital
Brain and Central Nervous System Tumors
Radiolabeled Monoclonal Antibody in Treating Patients With Glioblastoma Multiforme or Anaplastic Astrocytoma
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and deliver tumor-killing substances to them without harming normal cells. This may be an effective treatment for some types of brain tumors.
- Trial name
- NCT00004017
- Testing
- conventional surgery, iodine I 131 monoclonal antibody TNT-1/B
- Where
- 4 sites in United States
- Volunteers
- 60 people
- Sponsor
- Peregrine Pharmaceuticals
Medulloblastoma, Childhood
Children's and Adolescents' Medulloblastoma Molecular Subgroups in China
Recently, diagnosis and treatments for medulloblastoma becomes more complicated than before since the new World Health Organization (WHO) diagnosis criteria has put molecular marker onto an ever important position.
- Trial name
- CNOG-MB001 (NCT03288168)
- Where
- 9 sites in China
- Volunteers
- 200 people
- Sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Recurrent Glioma, Recurrent Glioblastoma
Talazoparib - Carboplatin for Recurrent High-grade Glioma With DDRd
In view of the strong biological rationale of employing PARP inhibition in high grade glioma, the current study purposes testing of talazoparib in a biomarker-enriched group of glioma.
- Conditions
- Recurrent Glioma, Recurrent Glioblastoma, Poly ADP Ribose Polymerase (PARP) Inhibitor, PTEN Gene Inactivation
- Trial name
- TAC-GReD (NCT04740190)
- Testing
- Talazoparib
- Where
- Hong Kong
- Volunteers
- 33 people
- Sponsor
- The University of Hong Kong
Brain and Central Nervous System Tumors
Lymphokine-Activated Killer Cells or Gliadel Wafer in Treating Patients With Newly Diagnosed Glioblastoma Multiforme That Can Be Removed by Surgery
RATIONALE: Biological therapies, such as lymphokine-activated killer cells, may stimulate the immune system in different ways and stop tumor cells from growing.
- Trial name
- NCT00814593
- Testing
- lymphokine-activated killer cells, polifeprosan 20 with carmustine implant
- Where
- United States
- Sponsor
- Lisata Therapeutics, Inc.
Primary Brain Tumour, Glioblastoma
OT SMILE: Occupational Therapy Group Intervention for Primary Brain Tumour Patients
People diagnosed with primary brain tumours often experience significant symptoms such as fatigue, cognitive changes, anxiety, and reduced ability to carry out everyday activities.
- Conditions
- Primary Brain Tumour, Glioblastoma, Brain Neoplasms
- Trial name
- OTSMILE (NCT07426848)
- Testing
- Standard Lifestyle Management Literature, OT SMILE Occupational Therapy Group Programme
- Where
- Ireland
- Volunteers
- 96 people
- Sponsor
- Royal College of Surgeons, Ireland
Low-grade Diffuse Glioma
Molecular Heterogeneity in Multilobar Low-grade Gliomas
Low-grade diffuse glioma (GDBG) are rare tumors of young adults, whose ontogenesis is poorly understood. Patient management is based on the molecular profile defined by two molecular markers : mutations of the IDH genes and…
- Trial name
- NCT04000048
- Testing
- sequencing of the complete exome
- Where
- France
- Volunteers
- 8 people
- Sponsor
- University Hospital, Montpellier
Glioblastoma
Hypofractionated Radiotherapy
This study was a multicenter, open-label, randomized, controlled, phase Ⅲ clinical trial to evaluate the efficacy and safety of hypofractionated concurrent radiotherapy followed by sequential temozolomide after surgery in…
- Trial name
- NCT06740955
- Testing
- hypofractionated postoperative radiotherapy, Conventionally fractionated postoperative radiotherapy
- Where
- China
- Volunteers
- 420 people
- Sponsor
- The First Hospital of Jilin University
High-grade Glioma, Solid Tumor, Unspecified, Child
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
An open label, non-randomized study in pediatric patients with advanced high-grade gliomas and other solid tumors. The study will be performed in two phases: a dose escalation phase in up to 18 patients following a standard "3+3"…
- Trial name
- NCT04299191
- Testing
- LAM561
- Where
- 3 sites in United States
- Volunteers
- 28 people
- Sponsor
- Laminar Pharmaceuticals
Medulloblastoma
Multicenter Pilot-study for the Therapy of Medulloblastoma of Adults
The purpose of this study is to determine whether a combination of a radiochemotherapy (vincristin) and a following maintenance chemotherapy (vincristin, cisplatin and CCNU) in adult patients with medulloblastoma is tolerable.
- Trial name
- NOA-07 (NCT01614132)
- Testing
- maintenance chemotherapy (vincristin, cisplatin and CCNU), Radiotherapy
- Where
- 15 sites in Germany
- Volunteers
- 33 people
- Sponsor
- University of Regensburg
Brain and Central Nervous System Tumors
Temozolomide Compared to Procarbazine, Lomustine, and Vincristine in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00052455
- Testing
- lomustine, procarbazine hydrochloride, temozolomide
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
Temozolomide in Relapsed or Advanced Anaplastic Oligodendroglioma and Oligoastrocytoma: Single-arm, Phase II Trial
The purpose of this study is to determine the efficacy and safety of temozolomide in patient with relapsed or advanced anaplastic oligodendroglioma and anaplastic oligoastrocytoma.
- Trial name
- NCT01847235
- Testing
- Temozolomide
- Where
- South Korea
- Volunteers
- 23 people
- Sponsor
- Seoul National University Hospital
Glioblastoma
Temozolomide Plus Anti-angiogenesis Drugs and Radiotherapy as a Treatment for Glioblastoma
Temozolomide (TMZ) is an oral chemotherapy drug. It is an alkylating agent used as a first-line treatment for glioblastoma. This methylation damages the DNA and triggers the death of tumor cells.
- Trial name
- NCT03567135
- Testing
- Apatinib, Temozolomide（TMZ）
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Fuzhou General Hospital
Low Grade Glioma
Vinblastine +/- Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)
This is an open-label, randomized, multi-center, comparator Phase II trial looking at the addition of Bevacizumab to Vinblastine in chemotherapy naïve pediatric patients with progressive Low Grade Glioma aged 6 months to less…
- Trial name
- NCT02840409
- Testing
- Vinblastine, Bevacizumab
- Where
- 21 sites in United States, Australia and 2 more
- Volunteers
- 109 people
- Sponsor
- The Hospital for Sick Children
Glioblastoma
Key Longitudinal Associations With Risk and Glioblastoma Outcomes
The goal of this observational study is to find out what factors affect the health and risks in adults with glioblastoma (GBM), a grade 4 brain cancer.
- Trial name
- Key LARGO (NCT06625684)
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Duke University
c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM
Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma
The study assessed the safety and the dose of the combination of INC280 and buparlisib (BKM120), as well as the anti-tumor activity of the combination, in patients with recurrent glioblastoma with PTEN mutations, homozygous…
- Trial name
- NCT01870726
- Testing
- INC280, Buparlisib
- Where
- 13 sites in United States, Germany and 3 more
- Volunteers
- 43 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4
A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)
The study aims to investigate the combination of the IDH1R132H peptide vaccine and the dual IDH1/2 inhibitor vorasidenib in patients with recurrent and/or progressive astrocytoma, WHO grade 2,3 and 4.
- Trial name
- iVOCAL (NCT07877415)
- Testing
- IDH1R132H-vac, Vorasidenib 40 mg Oral Tablet, Aldara - Imiquimod 5%
- Volunteers
- 45 people
- Sponsor
- Heidelberg University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.